Abivax announces annual general meeting details as company advances toward key 2025 value-driving milestones

Abivax announces annual general meeting details as company advances toward key 2025 value-driving milestones annual general meeting scheduled for friday, june 6, 2025, in paris, france phase 3 abtect induction trials remain on track: enrollment completion expected in q2 2025, with top-line induction results expected in q3 2025 paris, france – april 22, 2025 – 10:05 pm cest – abivax sa (euronext paris: fr0012333284 – abvx / nasdaq: abvx) (“abivax” or the “company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, today announced that the upcoming annual general meeting will be held on june 6, 2025, in paris, france. additional information and preparatory documents for this annual general meeting will be made available in the coming weeks in accordance with applicable legal and regulatory requirements.
ABVX Ratings Summary
ABVX Quant Ranking